News | August 02, 2007

RF Ablation Not Effective in Certain Ventricular Tachycardias

August, 3, 2007 - In patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), there is a high rate of recurrence following radiofrequency (RF) catheter ablation following electrophysiologic mapping, researchers report in the July 31st issue of the Journal of the American College of Cardiology.

"This study demonstrates that ventricular tachycardia in the setting of ARVD/C cannot be cured with RF catheter ablation," senior investigator Dr. Hugh Calkins told Reuters Health.

"These findings," he added, "also call into question the early use of RF ablation to treat ventricular tachycardia in this setting."

Dr. Calkins of the Johns Hopkins University School of Medicine in Baltimore and his colleagues note that previous studies of RF ablation for this inherited cardiomyopathy have yielded conflicting results.

To investigate further, the researchers followed 32 patients who had undergone at least one RF ablation procedure for ventricular tachycardia. In total, 48 procedures were performed. Of these, conventional mapping had been used for 38 procedures and the remaining ten employed three-dimensional electroanatomical mapping.

Seventy-seven per cent of the procedures resulted in ablation of ventricular tachycardias; these could not be re-induced with programmed electrical stimulation. However, clinical ventricular tachycardia was inducible in the other 23 per cent.

Overall, the researchers considered 46 per cent of the procedures to be successful, 31 per cent to be partially successful and 23 per cent of them to have failed. There was one procedure-related death.

The cumulative ventricular tachycardia recurrence-free survival rate was 75 per cent at six weeks, but this dropped to 25 per cent after 14 months. Cumulative recurrence-free survival had no significant association with the success or number of procedures, or with the mapping technique.

Until further data are available, the investigators recommend that "catheter ablation of ventricular tachycardia in patients with ARVD/C only be used as a palliative procedure to reduce the frequency of ventricular tachycardia episodes."

Source: Reuters
Author: David Douglas

Related Content

FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath
Technology | Ablation Systems | May 08, 2018
Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States....
Overlay Init